Lancet: Study Suggests Cheap Asthma Drug Budesonide Effective At Reducing CV Recovery Times

Chris Menahan
Aug. 12, 2021

A Texas doctor who started using and promoting this treatment to patients back in March 2020 was pilloried for it and censored on social media.

From The Pharmaceutical Journal:
Trial demonstrates efficacy of inhaled budesonide to treat COVID-19 in the community

Findings from the PRINCIPLE trial suggest that inhaled budesonide can improve recovery time and could reduce hospital admissions or death from COVID-19 if administered early.

By Julia Robinson | 11 August 2021

Inhaled budesonide should be considered for patients with COVID-19 who are at higher risk of complications in the community, according to results from a UK-wide clinical study.

The 'Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses' (PRINCIPLE) is the first randomised trial to demonstrate effectiveness of inhaled budesonide to treat COVID-19 in the community.

It builds on earlier evidence from the phase II 'Steroids in COVID-19' (STOIC) trial, which found that early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19.

Findings from the PRINCIPLE trial, published in the Lancet on 10 August 2021, suggested that inhaled budesonide improves recovery time and could potentially reduce hospital admissions or death.

Eligible participants included those who were aged 65 years or older, or aged 50 years or older with comorbidities, who had been unwell for up to 14 days with suspected COVID-19, but had not been admitted to hospital.

Overall, 4,700 participants were randomly assigned to either usual care (n=1,988), usual care plus 800μg of inhaled budesonide twice daily for 14 days (n=1,073), or usual care plus other interventions (n=1,639), and were then followed up for 28 days. The primary endpoints were time to first self-reported recovery, and hospital admission or death related to COVID-19, within 28 days.

Researchers found that, compared with the usual care group, participants using inhaled budesonide recovered an estimated 2.94 days sooner, had a greater sense of wellbeing while recovering and, once recovered, more often remained well.

For the hospital admission or death outcome, the estimated rate was 6.8% in the budesonide group, compared with 8.8% in the usual care group; although this failed to meet the superiority threshold.

[...] They added: "Overall, the consistency of these findings across both primary and secondary endpoints provides the strongest evidence thus far of an effective, safe, cheap and readily available treatment for COVID-19 in the community."

According to the authors of the study, early on in the COVID-19 pandemic, the low prevalence of asthma and chronic obstructive pulmonary disease among people admitted to hospital with COVID-19 led to speculation that the inhaled corticosteroids used to treat these conditions might be protective.
Texas doctor Richard Bartlett has been recommending inhaled budesonide since at least March, 2020 and getting a ton of flack for it.

Dr. Barlett said at the time he didn't want to follow the standard protocol of putting everyone on ventilators as around 90 percent of patients who received the "treatment" were dying.

You can find videos of his interviews all over BitChute -- most were banned off of YouTube.

A website he plugs has links to other studies suggesting it may be effective if used early at helping keep people from needing to be hospitalized.

Here's another study from Oxford University:
Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests

Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.

9 FEB 2021

The STOIC study found that inhaled budesonide given to patients with COVID-19 within seven days of the onset of symptoms also reduced recovery time. Budesonide is a corticosteroid used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD).

Findings from the phase 2 randomised study, which was supported by the NIHR Oxford Biomedical Research Centre (BRC), were published on the medRxiv pre-print server.

The findings from 146 people – of whom half took 800 micrograms of the medication twice a day and half were on usual care – suggests that inhaled budesonide reduced the relative risk of requiring urgent care or hospitalisation by 90% in the 28-day study period. Participants allocated the budesonide inhaler also had a quicker resolution of fever, symptoms and fewer persistent symptoms after 28 days.

Professor Mona Bafadhel of the University’s Nuffield Department of Medicine, who led the trial, said: 'There have been important breakthroughs in hospitalised COVID-19 patients, but equally important is treating early disease to prevent clinical deterioration and the need for urgent care and hospitalisation, especially to the billions of people worldwide who have limited access to hospital care.

'The vaccine programmes are really exciting, but we know that these will take some time to reach everyone across the world. I am heartened that a relatively safe, widely available and well studied medicine such as an inhaled steroid could have an impact on the pressures we are experiencing during the pandemic.'

The study also demonstrated that there was a reduction in persistent symptoms in those who received budesonide. Prof Bafadhel, a Respiratory Consultant also working at the Oxford University Hospitals NHS Foundation Trust, said: 'Although not the primary outcome of study, this is an important finding. I am encouraged to see the reduction in persistent symptoms at 14 and 28 days after treatment with budesonide. Persistent symptoms after the initial COVID-19 illness have emerged as a long-term problem. Any intervention which could address this would be a major step forward.'
I'd say it's rather shocking that this hasn't received more coverage but seeing as how there's no money in it and news outlets reporting on it face being censored by Big Tech I can't say I'm surprised.

Follow InformationLiberation on Twitter, Facebook, Gab, Minds, Parler and Telegram.

All original InformationLiberation articles CC 4.0

About - Privacy Policy